SCHEMBL2907448

SCHEMBL2907448

COc1ccc(C(Nc2cccc(C(=O)OC(C)(C)C)c2)c2cncs2)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS15 P98073 1/20 0.36
ABCB1 P08183 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
AURKA O14965 1/20 0.35
RPS6KB1 P23443 1/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35
GGPS1 O95749 5/20 0.34
FDPS P14324 3/20 0.34
ANO1 Q5XXA6 1/20 0.34
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
ROCK2 O75116 1/20 0.33
MAPK1 P28482 3/20 0.33
ALPL P05186 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908019 0.90 KCNQ3 (0.37) TMPRSS15AURKARPS6KB1LMNAROCK2
SCHEMBL2908813 0.86 MKNK1 (0.35) TMPRSS15ABCB1ABCG2AURKARPS6KB1
SCHEMBL3129124 0.79 SMN1; SMN2 (0.37) KMT2ALMNAMAPK1MEN1NPC1
SCHEMBL2908192 0.77 IMPDH2 (0.36) ABCG2AURKAHTR1AHTR7KMT2A
SCHEMBL2905041 0.77 CD38 (0.36) AURKARPS6KB1KMT2AALPLMEN1
SCHEMBL3123717 0.76 TSHR (0.47) KMT2ALMNAMEN1NPC1MAPT
SCHEMBL2910339 0.72 MAPK1 (0.42) KMT2ALMNAMAPK1ALPLMEN1
SCHEMBL2909821 0.72 LMNA (0.45) LMNAMAPK1NPC1MAPTRAB9A
SCHEMBL2910933 0.71 PDE4D (0.40) ABCB1ABCG2KMT2ALMNAALPL
SCHEMBL2908203 0.71 MKNK1 (0.45) ABCB1ABCG2KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B TMPRSS15 1290/4885ABCB1 829/4885ABCG2 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.